Phase III study of fluorouracil, leucovorin, and levamisole in high-risk stage II and III colon cancer: Final report of intergroup 0089

Journal of Clinical Oncology

Volumn 23, Issue 34, 2005, Pages 8671-8678

  Haller, Daniel G ^a   Catalano, Paul J ^a   Macdonald, John S ^a   O'Rourke, Mark A ^a   Frontiera, Michael S ^a   Jackson, Don V ^a   Mayer, Robert J ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLUOROURACIL; FOLINIC ACID; LEVAMISOLE; ANTINEOPLASTIC AGENT; IMMUNOLOGICAL ADJUVANT; VITAMIN B COMPLEX;

ADJUVANT THERAPY; ADULT; ARTICLE; CANCER CHEMOTHERAPY; CANCER RESEARCH; CANCER RISK; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; COLON CANCER; COLONOSCOPY; COMBINATION CHEMOTHERAPY; COMORBIDITY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG MEGADOSE; FEMALE; FOLLOW UP; GRANULOCYTOPENIA; HIGH RISK PATIENT; HUMAN; LOW DRUG DOSE; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NEUROLOGIC DISEASE; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEX DIFFERENCE; STOMATITIS; TOXICITY; TREATMENT OUTCOME; ADENOCARCINOMA; AGED; AGRANULOCYTOSIS; CHEMICALLY INDUCED DISORDER; COLON TUMOR; COMPARATIVE STUDY; DOSE RESPONSE; MIDDLE AGED; PATHOLOGY; PATIENT COMPLIANCE; RISK FACTOR; SURVIVAL; TUMOR RECURRENCE;

ADENOCARCINOMA; ADJUVANTS, IMMUNOLOGIC; ADULT; AGED; AGRANULOCYTOSIS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COLONIC NEOPLASMS; DIARRHEA; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FLUOROURACIL; FOLLOW-UP STUDIES; HUMANS; LEUCOVORIN; LEVAMISOLE; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PATIENT COMPLIANCE; RISK FACTORS; SURVIVAL ANALYSIS; TREATMENT OUTCOME; VITAMIN B COMPLEX;

EID: 33644846283     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2004.00.5686     Document Type: Article

References (32)

1. Buyse M, Zeleniuch-Jacquotte A, Chalmers TC: Adjuvant therapy of colorectal cancer: Why we still don't know. JAMA 259:3571-3578, 1988
2. Laurie JA, Moertel CG, Fleming TR, et al: Surgical adjuvant therapy of large bowel adenocarcinoma: An evaluation of levamisole and the combination of levamisole and 5-FU. J Clin Oncol 7:1447-1456, 1989
3. Piedbois P, Buyse M: What can we learn from a meta-analysis of trials testing the modulation of 5-FU by leucovorin? Advanced Colorectal Meta-Analysis Project. Ann Oncol 4:15-19, 1993 (suppl 2)
4. O'Connell MJ, Kahn MJ, Erlichman C, et al: Optimal duration of FU plus levamisole colon cancer surgical adjuvant therapy. J Clin Oncol 14:2887, 1996
5. Wolmark N, Rockette H, Mamounas E, et al: Clinical trial to assess the relative efficacy of FU and leucovorin, FU and levamisole, and FU, leucovorin, and levamisole in patients with Dukes' B and C carcinoma of the colon: Results from National Surgical Adjuvant Breast and Bowel Project C-04. J Clin Oncol 17:3553-3559, 1999
6. Moertel CG, Fleming TR, Macdonald JS, et al: Levamisole and FU for adjuvant therapy of resected colon carcinoma. N Engl J Med 322: 352-358, 1990
7. Moertel CG, Fleming TR, Macdonald JS, et al: FU plus levamisole as effective adjuvant therapy after resection of stage III colon carcinoma: A final report. Ann Intern Med 122:321-326, 1995
8. Zelen M: The randomization and stratification of patients to clinical trials. J Chronic Dis 27:365-375, 1974
9. Mehta CR, Patel NR, Tsiatis AA: Exact significance testing to establish treatment equivalence with ordered categorical data. Biometrics 40:819-825, 1984
10. Kaplan EL, Meier P: Non-parametric estimation of incomplete observations. J Am Stat Assoc 53:457-481, 1958
11. Mantel N: Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 50:163-170, 1966
12. Cox DR: Regression models and life tables. J R Stat Soc 34:187-202, 1972
13. Gill S, Loprinzi CL, Sargent DJ, et al: Pooled analysis of FU-based adjuvant therapy for stage II and III colon cancer: Who benefits and by how much? J Clin Oncol 22:1797-1806, 2004
14. Greene FL, Stewart AK, Norton HJ: A new TNM staging strategy for node-positive (stage III) colon cancer: An analysis of 50,042 patients. Ann Surg 236:416-421, 2002
15. Greene FL, Stewart AK, Norton HJ: New tumor-node-metastasis staging strategy for node-positive (stage III) rectal cancer: An analysis. J Clin Oncol 22:1778-1784, 2004
16. Gunderson LL, Sargent DJ, Tepper JE, et al: Impact of T and N stage and treatment on survival and relapse in adjuvant rectal cancer: A pooled analysis. J Clin Oncol 22:1785-1796, 2004
17. McCollum AD, Catalano PJ, Haller DG, et al: Outcomes and toxicity in African-American and Caucasian patients in a randomized adjuvant chemotherapy trial for colon cancer. J Natl Cancer Inst 94:1160-1167, 2002
18. Efficacy of adjuvant FU and folinic acid in colon cancer: International Multicentre Pooled Analysis of Colon Cancer Trials (IMPACT) investigators. Lancet 345:939-944, 1995
19. Comparison of fluorouracil with additional levamisole, higher-dose folinic acid, or both, as adjuvant chemotherapy for colorectal cancer: A randomised trial-QUASAR Collaborative Group. Lancet 355:1588-1596, 2000
20. Buroker TR, O'Connell MJ, Wieand HS: Randomized comparison of two schedules of FU and leucovorin in the treatment of advanced colorectal cancer. J Clin Oncol 12:14-20, 1994
21. Sargent DJ, Weiand S, Benedetti J, et al: Disease-free survival (DFS) vs. overall survival (OS) as a primary endpoint for adjuvant colon cancer studies: Individual patient data from 12,915 patients on 15 randomized trials. J Clin Oncol 22:245s, 2004 (suppl; abstr 3502)
22. Sargent DJ: Endpoints for colon adjuvant trials: Recommendations made from independent patient data from 20898 patients and 18 randomized trials. J Clin Oncol 23:249s, 2005 (suppl; abstr 3512)
23. O'Connell MJ, Wolmark N, Yothers G, et al: Durable improvement in disease-free survival (DFS) and overall survival (OS) for stage II or III colon cancer treated with leucovorin-modulated fluorouracil (FL): 10-year follow-up of National Surgical Adjuvant Breast and Bowel Project (NSABP) protocol C-03. J Clin Oncol 23:248s, 2005 (suppl; abstr 3511)
24. Sargent DJ, Goldberg RM, Jacobson SD, et al: A pooled analysis of adjuvant chemotherapy for resected colon cancer in elderly patients. N Engl J Med 345:1091-1097, 2001
25. Schrag D, Cramer LD, Bach PB, et al: Age and adjuvant chemotherapy use after surgery for stage III colon cancer. J Natl Cancer Inst 93:850-857, 2001
26. Meyerhardt JA, Catalano PJ, Haller DG, et al: Influence of body mass index on outcomes and treatment-related toxicity in patients with colon carcinoma. Cancer 98:484-495, 2003
27. Meyerhardt JA, Catalano PJ, Haller DG, et al: Impact of diabetes mellitus on outcomes in patients with colon cancer. J Clin Oncol 21:433-440, 2003
28. Green RJ, Metlay JP, Propert K, et al: Surveillance for second primary colorectal cancer after adjuvant chemotherapy: An analysis of Intergroup 0089. Ann Intern Med 136:261-269, 2002
29. Joseph NE, Sigurdson ER, Hanlon AL, et al: Accuracy of determining nodal negativity in colorectal cancer on the basis of the number of nodes retrieved on resection. Ann Surg Oncol 10:213-218, 2003
30. Le Voyer TE, Sigurdson ER, Hanlon AL, et al: Colon cancer survival is associated with increasing number of lymph nodes analyzed: A secondary survey of intergroup trial INT-0089. J Clin Oncol 21:2912-2919, 2003
31. Meyerhardt JA, Catalano PJ, Schrag D, et al: Association of hospital procedure volume and outcomes in patients with colon cancer at high risk for recurrence. Ann Intern Med 139:649-657, 2003
32. Andre T, Boni C, Mounedji-Boudiaf L, et al: Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 350:2343-2351, 2004